Sirturo patents expiration

SIRTURO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498343 JANSSEN THERAP Mycobacterial inhibitors
Dec, 2026

(3 years from now)

US8546428 JANSSEN THERAP Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
Mar, 2029

(5 years from now)

Sirturo is owned by Janssen Therap.

Sirturo contains Bedaquiline Fumarate.

Sirturo has a total of 2 drug patents out of which 0 drug patents have expired.

Sirturo was authorised for market use on 28 December, 2012.

Sirturo is available in tablet;oral dosage forms.

Sirturo can be used as treatment of pulmonary multi-drug resistant tuberculosis.

The generics of Sirturo are possible to be released after 19 March, 2029.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2027

Drugs and Companies using BEDAQUILINE FUMARATE ingredient

Market Authorisation Date: 28 December, 2012

Treatment: Treatment of pulmonary multi-drug resistant tuberculosis


More Information on Dosage

SIRTURO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic